This is the biggest winner of all the stocks out there. This is the first question he has ever had on this stock in 17 years. Don’t hold your breath on stock splits. The CEO does not believe in them.

His model price is $71.65, a 17% downside. It is cheap in its balance sheet. The fundamentals are coming up to meet the stock price. He thinks the action will be elsewhere in 2017. There is potential upside as the earnings come in.

You have not been able to buy this stock at its model price since 2012. It has come back to that price. He is positive on this stock. $60.16 is the model price. We will see how drugs work in 2017.

ORCL-Q Vs. IBM-N. IBM-N works hard on their balance sheet. ORCL-Q is old tech. He bought ORCL-Q at $12 a share. He likes it and it probably has the most upside. His model price is $46.11, or 0% upside, but IBM is $165.03, trading right on its model price also. He likes the diversification of both.

ORCL-Q Vs. IBM-N. IBM-N works hard on their balance sheet. ORCL-Q is old tech. He bought ORCL-Q at $12 a share. He likes it and it probably has the most upside. His model price is $46.11, or 0% upside, but IBM is $165.03, trading right on its model price also. He likes the diversification of both.

His model price is $68.16. If it went down in price he would be a buyer but it trades right on its model price usually.

He loves it. It is coming out of the blue. The regional banks trade at higher valuations. He is looking for BAC-N to benefit from less regulation and more dividend increases. He is looking for an increase in the first quarter.